BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mørk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sánchez C. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340:666-675. [PMID: 22171087 DOI: 10.1124/jpet.111.189068] [Cited by in Crossref: 181] [Cited by in F6Publishing: 152] [Article Influence: 18.1] [Reference Citation Analysis]
Number Citing Articles
1 Fu J, Peng L, Li X. The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis. Neuropsychiatr Dis Treat 2016;12:951-9. [PMID: 27143896 DOI: 10.2147/NDT.S104050] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
2 Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. Journal of Affective Disorders 2016;206:140-50. [DOI: 10.1016/j.jad.2016.07.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 6.6] [Reference Citation Analysis]
3 Nierenberg A, Loft H, Olsen C. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine. Journal of Affective Disorders 2019;250:35-42. [DOI: 10.1016/j.jad.2019.02.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
4 Artigas F, Bortolozzi A, Celada P. Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies. Eur Neuropsychopharmacol 2018;28:445-56. [PMID: 29174531 DOI: 10.1016/j.euroneuro.2017.10.032] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 10.8] [Reference Citation Analysis]
5 Connolly KR, Thase ME. Vortioxetine: a New Treatment for Major Depressive Disorder. Expert Opinion on Pharmacotherapy 2016;17:421-31. [DOI: 10.1517/14656566.2016.1133588] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 7.2] [Reference Citation Analysis]
6 Artigas F. Developments in the field of antidepressants, where do we go now? Eur Neuropsychopharmacol 2015;25:657-70. [PMID: 23706576 DOI: 10.1016/j.euroneuro.2013.04.013] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
7 Torrisi SA, Geraci F, Tropea MR, Grasso M, Caruso G, Fidilio A, Musso N, Sanfilippo G, Tascedda F, Palmeri A, Salomone S, Drago F, Puzzo D, Leggio GM, Caraci F. Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by Aβ1-42 Oligomers in Mice: A Key Role of Transforming Growth Factor-β1. Front Pharmacol 2019;10:693. [PMID: 31293421 DOI: 10.3389/fphar.2019.00693] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
8 Beyeler A, Ju A, Chagraoui A, Cuvelle L, Teixeira M, Di Giovanni G, De Deurwaerdère P. Multiple facets of serotonergic modulation. Prog Brain Res 2021;261:3-39. [PMID: 33785133 DOI: 10.1016/bs.pbr.2021.02.002] [Reference Citation Analysis]
9 Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry 2014;14:276. [PMID: 25260373 DOI: 10.1186/s12888-014-0276-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
10 Martin V, Riffaud A, Marday T, Brouillard C, Franc B, Tassin JP, Sevoz-Couche C, Mongeau R, Lanfumey L. Response of Htr3a knockout mice to antidepressant treatment and chronic stress. Br J Pharmacol 2017;174:2471-83. [PMID: 28493335 DOI: 10.1111/bph.13857] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
11 Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat 2015;11:875-88. [PMID: 25848287 DOI: 10.2147/NDT.S73261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
12 Christensen MC, Florea I, Lindsten A, Baldwin DS. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol 2018;32:1086-97. [PMID: 30047820 DOI: 10.1177/0269881118788826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
13 Shalimova A, Babasieva V, Chubarev VN, Tarasov VV, Schiöth HB, Mwinyi J. Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics 2021;22:485-503. [PMID: 34018822 DOI: 10.2217/pgs-2020-0157] [Reference Citation Analysis]
14 Pytka K, Głuch-Lutwin M, Kotańska M, Waszkielewicz A, Kij A, Walczak M. Single Administration of HBK-15-a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist-Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone. Mol Neurobiol 2018;55:3931-45. [PMID: 28550529 DOI: 10.1007/s12035-017-0605-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
15 Leiser SC, Iglesias-Bregna D, Westrich L, Pehrson AL, Sanchez C. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism. J Psychopharmacol 2015;29:1092-105. [PMID: 26174134 DOI: 10.1177/0269881115592347] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
16 Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. European Neuropsychopharmacology 2016;26:979-93. [DOI: 10.1016/j.euroneuro.2016.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 13.8] [Reference Citation Analysis]
17 Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014;28:855-74. [PMID: 25145538 DOI: 10.1007/s40263-014-0195-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
18 Martins J, S B. Phytochemistry and pharmacology of anti-depressant medicinal plants: A review. Biomed Pharmacother 2018;104:343-65. [PMID: 29778018 DOI: 10.1016/j.biopha.2018.05.044] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 8.7] [Reference Citation Analysis]
19 Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, Claeysen S, Cunningham KA, Fone KC, Gershon M, Di Giovanni G, Goodfellow NM, Halberstadt AL, Hartley RM, Hassaine G, Herrick-Davis K, Hovius R, Lacivita E, Lambe EK, Leopoldo M, Levy FO, Lummis SCR, Marin P, Maroteaux L, McCreary AC, Nelson DL, Neumaier JF, Newman-Tancredi A, Nury H, Roberts A, Roth BL, Roumier A, Sanger GJ, Teitler M, Sharp T, Villalón CM, Vogel H, Watts SW, Hoyer D. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacol Rev 2021;73:310-520. [PMID: 33370241 DOI: 10.1124/pr.118.015552] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
20 Bétry C, Overstreet D, Haddjeri N, Pehrson A, Bundgaard C, Sanchez C, Mørk A. A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant. Pharmacology Biochemistry and Behavior 2015;131:136-42. [DOI: 10.1016/j.pbb.2015.02.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
21 Gonda X, Pompili M, Serafini G, Carvalho AF, Rihmer Z, Dome P. The role of cognitive dysfunction in the symptoms and remission from depression. Ann Gen Psychiatry 2015;14:27. [PMID: 26396586 DOI: 10.1186/s12991-015-0068-9] [Cited by in Crossref: 82] [Cited by in F6Publishing: 58] [Article Influence: 13.7] [Reference Citation Analysis]
22 Brito AF, Braga PCCS, Moreira LKS, Silva DM, Silva DPB, Sanz G, Vaz BG, de Carvalho FS, Lião LM, Silva RR, Noël F, Neri HFS, Ghedini PC, de Carvalho MF, de S. Gil E, Costa EA, Menegatti R. A new piperazine derivative: 1-(4-(3,5-di-tert-butyl-4-hydroxybenzyl) piperazin-1-yl)-2-methoxyethan-1-one with antioxidant and central activity. Naunyn-Schmiedeberg's Arch Pharmacol 2018;391:255-69. [DOI: 10.1007/s00210-017-1451-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
23 Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology 2015;40:2025-37. [PMID: 25687662 DOI: 10.1038/npp.2015.52] [Cited by in Crossref: 160] [Cited by in F6Publishing: 117] [Article Influence: 26.7] [Reference Citation Analysis]
24 Bétry C, Etiévant A, Pehrson A, Sánchez C, Haddjeri N. Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2015;58:38-46. [DOI: 10.1016/j.pnpbp.2014.12.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
25 Mørk A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M, Sanchez C. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav 2013;105:41-50. [PMID: 23380522 DOI: 10.1016/j.pbb.2013.01.019] [Cited by in Crossref: 100] [Cited by in F6Publishing: 81] [Article Influence: 12.5] [Reference Citation Analysis]
26 Yi Y, Ren G, Zheng M, Zhao D, Li N, Chen X, Lu Y. Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers. Journal of Chromatography B 2020;1138:121955. [DOI: 10.1016/j.jchromb.2019.121955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Riga MS, Teruel-martí V, Sánchez C, Celada P, Artigas F. Subchronic vortioxetine treatment –but not escitalopram– enhances pyramidal neuron activity in the rat prefrontal cortex. Neuropharmacology 2017;113:148-55. [DOI: 10.1016/j.neuropharm.2016.09.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
28 Chilmonczyk Z, Bojarski AJ, Pilc A, Sylte I. Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands. Int J Mol Sci 2015;16:18474-506. [PMID: 26262615 DOI: 10.3390/ijms160818474] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
29 Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015;232:2061-70. [PMID: 25575488 DOI: 10.1007/s00213-014-3839-0] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
30 Wilson S, Højer AM, Buchberg J, Areberg J, Nutt DJ. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. J Psychopharmacol 2015;29:1085-91. [PMID: 26253622 DOI: 10.1177/0269881115599387] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
31 Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother 2014;15:2525-42. [PMID: 25224953 DOI: 10.1517/14656566.2014.960842] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
32 Delcourte S, Etievant A, Haddjeri N. Role of central serotonin and noradrenaline interactions in the antidepressants' action: Electrophysiological and neurochemical evidence. Prog Brain Res 2021;259:7-81. [PMID: 33541681 DOI: 10.1016/bs.pbr.2021.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Tritschler L, Felice D, Colle R, Guilloux J, Corruble E, Gardier AM, David DJ. Vortioxetine for the treatment of major depressive disorder. Expert Review of Clinical Pharmacology 2014;7:731-45. [DOI: 10.1586/17512433.2014.950655] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
34 Fernández-pastor B, Ortega JE, Meana JJ. Involvement of serotonin 5-HT3 receptors in the modulation of noradrenergic transmission by serotonin reuptake inhibitors: a microdialysis study in rat brain. Psychopharmacology 2013;229:331-44. [DOI: 10.1007/s00213-013-3112-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
35 Wegener G, Mathe AA, Neumann ID. Selectively Bred Rodents as Models of Depression and Anxiety. In: Cryan JF, Reif A, editors. Behavioral Neurogenetics. Berlin: Springer Berlin Heidelberg; 2012. pp. 139-87. [DOI: 10.1007/7854_2011_192] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
36 Sparling BA, Dimauro EF. Progress in the discovery of small molecule modulators of the Cys-loop superfamily receptors. Bioorganic & Medicinal Chemistry Letters 2017;27:3207-18. [DOI: 10.1016/j.bmcl.2017.04.073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
37 Wallace A, Pehrson AL, Sánchez C, Morilak DA. Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. Int J Neuropsychopharmacol 2014;17:1695-706. [PMID: 24852131 DOI: 10.1017/S1461145714000571] [Cited by in Crossref: 72] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
38 Millan MJ. On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. Int J Neuropsychopharmacol 2014;17:1009-37. [PMID: 23719026 DOI: 10.1017/S1461145712001496] [Cited by in Crossref: 47] [Cited by in F6Publishing: 12] [Article Influence: 5.9] [Reference Citation Analysis]
39 Findling RL, Robb AS, DelBello MP, Huss M, McNamara NK, Sarkis EH, Scheffer RE, Poulsen LH, Chen G, Lemming OM, Auby P. A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders. J Child Adolesc Psychopharmacol 2018;28:47-54. [PMID: 29035574 DOI: 10.1089/cap.2017.0047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
40 Nackenoff AG, Simmler LD, Baganz NL, Pehrson AL, Sánchez C, Blakely RD. Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine As Revealed Using the SERT Met172 Mouse. ACS Chem Neurosci 2017;8:1092-100. [DOI: 10.1021/acschemneuro.7b00038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
41 Nissen TD, Laursen B, Viardot G, l'Hostis P, Danjou P, Sluth LB, Gram M, Bastlund JF, Christensen SR, Drewes AM. Effects of Vortioxetine and Escitalopram on Electroencephalographic Recordings – A Randomized, Crossover Trial in Healthy Males. Neuroscience 2020;424:172-81. [DOI: 10.1016/j.neuroscience.2019.09.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
42 McIntyre RS, Loft H, Christensen MC. Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder. Neuropsychiatr Dis Treat 2021;17:575-85. [PMID: 33654400 DOI: 10.2147/NDT.S296451] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters. CNS Spectr 2015;20:515-9. [DOI: 10.1017/s1092852915000358] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.2] [Reference Citation Analysis]
44 Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord 2018;227:803-9. [PMID: 29673132 DOI: 10.1016/j.jad.2017.11.053] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
45 Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV. Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. European Neuropsychopharmacology 2012;22:858-66. [DOI: 10.1016/j.euroneuro.2012.07.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
46 Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine. CNS Spectr 2015;20:455-9. [DOI: 10.1017/s1092852915000346] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
47 Biederman J, Lindsten A, Sluth LB, Petersen ML, Ettrup A, Eriksen HF, Fava M. Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study. J Psychopharmacol 2019;33:511-21. [PMID: 30843450 DOI: 10.1177/0269881119832538] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
48 Mahableshwarkar AR, Jacobsen PL, Chen Y, Simon JS. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract 2014;68:49-59. [DOI: 10.1111/ijcp.12328] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
49 Kurhe Y, Mahesh R, Devadoss T. Novel 5-HT3 receptor antagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice. Psychopharmacology 2017;234:1165-79. [DOI: 10.1007/s00213-017-4558-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
50 Rannversson H, Andersen J, Sørensen L, Bang-Andersen B, Park M, Huber T, Sakmar TP, Strømgaard K. Genetically encoded photocrosslinkers locate the high-affinity binding site of antidepressant drugs in the human serotonin transporter. Nat Commun 2016;7:11261. [PMID: 27089947 DOI: 10.1038/ncomms11261] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 7.6] [Reference Citation Analysis]
51 Chen G, Nomikos GG, Affinito J, Zhao Z. Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium. Clin Pharmacokinet 2016;55:1115-27. [PMID: 27048210 DOI: 10.1007/s40262-016-0389-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
52 Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav 2017;7:e00622. [PMID: 28293465 DOI: 10.1002/brb3.622] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
53 Turan Yücel N, Kandemir Ü, Demir Özkay Ü, Can ÖD. 5-HT1A Serotonergic, α-Adrenergic and Opioidergic Receptors Mediate the Analgesic Efficacy of Vortioxetine in Mice. Molecules 2021;26:3242. [PMID: 34071269 DOI: 10.3390/molecules26113242] [Reference Citation Analysis]
54 Bobo W, Kelliny M, Croarkin P, Moore K. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. TCRM. [DOI: 10.2147/tcrm.s55313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
55 Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Buonaguro EF, Vellante F, Fornaro M, Fiengo A, Mazza M, Vecchiotti R, Perna G, de Bartolomeis A, Martinotti G, Di Giannantonio M, De Berardis D. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Rev Neurother 2016;16:483-95. [PMID: 27050932 DOI: 10.1586/14737175.2016.1173545] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
56 Matsuno K, Nakamura K, Aritomi Y, Nishimura A. Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults. Clin Pharmacol Drug Dev 2018;7:319-31. [PMID: 28941196 DOI: 10.1002/cpdd.381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
57 Köhler S, Cierpinsky K, Kronenberg G, Adli M. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. J Psychopharmacol 2016;30:13-22. [DOI: 10.1177/0269881115609072] [Cited by in Crossref: 73] [Cited by in F6Publishing: 50] [Article Influence: 14.6] [Reference Citation Analysis]
58 Kędzierska E, Fiorino F, Magli E, Poleszak E, Wlaź P, Orzelska-górka J, Knap B, Kotlińska JH. New arylpiperazine derivatives with antidepressant-like activity containing isonicotinic and picolinic nuclei: evidence for serotonergic system involvement. Naunyn-Schmiedeberg's Arch Pharmacol 2019;392:743-54. [DOI: 10.1007/s00210-019-01620-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
59 du Jardin KG, Liebenberg N, Müller HK, Elfving B, Sanchez C, Wegener G. Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. Psychopharmacology (Berl) 2016;233:2813-25. [PMID: 27236785 DOI: 10.1007/s00213-016-4327-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
60 Deardorff WJ, Grossberg GT. The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly. Curr Geri Rep 2015;4:301-11. [DOI: 10.1007/s13670-015-0140-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
61 Sharp T, Barnes NM. Central 5-HT receptors and their function; present and future. Neuropharmacology 2020;177:108155. [PMID: 32522572 DOI: 10.1016/j.neuropharm.2020.108155] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 21.0] [Reference Citation Analysis]
62 Perez-Palomar B, Mollinedo-Gajate I, Berrocoso E, Meana JJ, Ortega JE. Serotonin 5-HT3 receptor antagonism potentiates the antidepressant activity of citalopram. Neuropharmacology 2018;133:491-502. [PMID: 29477299 DOI: 10.1016/j.neuropharm.2018.02.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
63 du Jardin KG, Müller HK, Sanchez C, Wegener G, Elfving B. A single dose of vortioxetine, but not ketamine or fluoxetine, increases plasticity-related gene expression in the rat frontal cortex. Eur J Pharmacol 2016;786:29-35. [PMID: 27235984 DOI: 10.1016/j.ejphar.2016.05.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
64 Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
65 Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. CNS Spectr 2017;22:348-62. [PMID: 27869048 DOI: 10.1017/S1092852916000626] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 2.2] [Reference Citation Analysis]
66 Riga MS, Sánchez C, Celada P, Artigas F. Involvement of 5-HT 3 receptors in the action of vortioxetine in rat brain: Focus on glutamatergic and GABAergic neurotransmission. Neuropharmacology 2016;108:73-81. [DOI: 10.1016/j.neuropharm.2016.04.023] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
67 Westrich L, Haddjeri N, Dkhissi-benyahya O, Sánchez C. Involvement of 5-HT7 receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents. Neuropharmacology 2015;89:382-90. [DOI: 10.1016/j.neuropharm.2014.10.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
68 Pehrson AL, Leiser SC, Gulinello M, Dale E, Li Y, Waller JA, Sanchez C. Treatment of cognitive dysfunction in major depressive disorder—a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. European Journal of Pharmacology 2015;753:19-31. [DOI: 10.1016/j.ejphar.2014.07.044] [Cited by in Crossref: 59] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
69 Blier P, El Mansari M. Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci 2013;368:20120536. [PMID: 23440470 DOI: 10.1098/rstb.2012.0536] [Cited by in Crossref: 130] [Cited by in F6Publishing: 102] [Article Influence: 16.3] [Reference Citation Analysis]
70 Vasefi MS, Kruk JS, Heikkila JJ, Beazely MA. 5-Hydroxytryptamine type 7 receptor neuroprotection against NMDA-induced excitotoxicity is PDGFβ receptor dependent. J Neurochem 2013;125:26-36. [PMID: 23336565 DOI: 10.1111/jnc.12157] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
71 Adamo D, Pecoraro G, Coppola N, Calabria E, Aria M, Mignogna M. Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open-label randomized trial. Oral Dis 2021;27:1022-41. [PMID: 32790904 DOI: 10.1111/odi.13602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
72 Okada M, Matsumoto R, Yamamoto Y, Fukuyama K. Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor. Int J Mol Sci 2021;22:1351. [PMID: 33572981 DOI: 10.3390/ijms22031351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
73 Dale E, Pehrson AL, Jeyarajah T, Li Y, Leiser SC, Smagin G, Olsen CK, Sanchez C. Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function. CNS Spectr 2016;21:143-61. [PMID: 26346726 DOI: 10.1017/S1092852915000425] [Cited by in Crossref: 65] [Cited by in F6Publishing: 27] [Article Influence: 10.8] [Reference Citation Analysis]
74 Leiser SC, Li Y, Pehrson AL, Dale E, Smagin G, Sanchez C. Serotonergic Regulation of Prefrontal Cortical Circuitries Involved in Cognitive Processing: A Review of Individual 5-HT Receptor Mechanisms and Concerted Effects of 5-HT Receptors Exemplified by the Multimodal Antidepressant Vortioxetine. ACS Chem Neurosci 2015;6:970-86. [DOI: 10.1021/cn500340j] [Cited by in Crossref: 68] [Cited by in F6Publishing: 51] [Article Influence: 11.3] [Reference Citation Analysis]
75 Patel K, Abdool PS, Rajji TK, Mulsant BH. Pharmacotherapy of major depression in late life: what is the role of new agents? Expert Opinion on Pharmacotherapy 2017;18:599-609. [DOI: 10.1080/14656566.2017.1308484] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
76 Alam MY, Jacobsen PL, Chen Y, Serenko M, Mahableshwarkar AR. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2014;29:36-44. [PMID: 24169027 DOI: 10.1097/yic.0000000000000010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 17] [Article Influence: 5.6] [Reference Citation Analysis]
77 Chen G, Zhang W, Serenko M. Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. The Journal of Clinical Pharmacology 2015;55:671-9. [DOI: 10.1002/jcph.456] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
78 David DJ, Tritschler L, Guilloux JP, Gardier AM, Sanchez C, Gaillard R. [Pharmacological properties of vortioxetine and its pre-clinical consequences]. Encephale 2016;42:1S12-23. [PMID: 26879252 DOI: 10.1016/S0013-7006(16)30015-X] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
79 Sagud M, Nikolac Perkovic M, Vuksan-cusa B, Maravic A, Svob Strac D, Mihaljevic Peles A, Zivkovic M, Kusevic Z, Pivac N. A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. Psychopharmacology 2016;233:3259-67. [DOI: 10.1007/s00213-016-4364-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
80 McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17:1557-67. [PMID: 24787143 DOI: 10.1017/S1461145714000546] [Cited by in Crossref: 205] [Cited by in F6Publishing: 67] [Article Influence: 29.3] [Reference Citation Analysis]
81 Gupta D, Prabhakar V, Radhakrishnan M. 5HT3 receptors: Target for new antidepressant drugs. Neurosci Biobehav Rev 2016;64:311-25. [PMID: 26976353 DOI: 10.1016/j.neubiorev.2016.03.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
82 Kurhe Y, Mahesh R. Ondansetron ameliorates depression associated with obesity in high-fat diet fed experimental mice: An investigation-based on the behavioral, biochemical, and molecular approach. Indian J Pharmacol 2017;49:290-6. [PMID: 29326489 DOI: 10.4103/ijp.IJP_805_16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Findling RL, Robb AS, DelBello M, Huss M, McNamara N, Sarkis E, Scheffer R, Poulsen LH, Chen G, Lemming OM, Areberg J, Auby P. Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients. J Child Adolesc Psychopharmacol 2017;27:526-34. [PMID: 28333546 DOI: 10.1089/cap.2016.0155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
84 du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. European Neuropsychopharmacology 2014;24:160-71. [DOI: 10.1016/j.euroneuro.2013.07.001] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 11.1] [Reference Citation Analysis]
85 Perna G, Alciati A, Riva A, Micieli W, Caldirola D. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Curr Psychiatry Rep 2016;18. [DOI: 10.1007/s11920-016-0668-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 7.4] [Reference Citation Analysis]
86 Vieta E, Loft H, Florea I. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder. European Neuropsychopharmacology 2017;27:877-84. [DOI: 10.1016/j.euroneuro.2017.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
87 Okada M, Okubo R, Fukuyama K. Vortioxetine Subchronically Activates Serotonergic Transmission via Desensitization of Serotonin 5-HT1A Receptor with 5-HT3 Receptor Inhibition in Rats. Int J Mol Sci 2019;20:E6235. [PMID: 31835640 DOI: 10.3390/ijms20246235] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
88 Pytka K, Partyka A, Jastrzębska-Więsek M, Siwek A, Głuch-Lutwin M, Mordyl B, Kazek G, Rapacz A, Olczyk A, Gałuszka A, Błachuta M, Waszkielewicz A, Marona H, Sapa J, Filipek B, Wesołowska A. Antidepressant- and Anxiolytic-Like Effects of New Dual 5-HT₁A and 5-HT₇ Antagonists in Animal Models. PLoS One 2015;10:e0142499. [PMID: 26554929 DOI: 10.1371/journal.pone.0142499] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
89 Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015;14:1291-304. [PMID: 26022537 DOI: 10.1517/14740338.2015.1046836] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
90 Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 2018;14:81-9. [DOI: 10.1080/17460441.2019.1546691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
91 Morimoto SS, Kanellopoulos D, Manning KJ, Alexopoulos GS. Diagnosis and treatment of depression and cognitive impairment in late life. Ann N Y Acad Sci 2015;1345:36-46. [PMID: 25655026 DOI: 10.1111/nyas.12669] [Cited by in Crossref: 61] [Cited by in F6Publishing: 34] [Article Influence: 10.2] [Reference Citation Analysis]
92 Felice D, Guilloux JP, Pehrson A, Li Y, Mendez-David I, Gardier AM, Sanchez C, David DJ. Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism. Front Pharmacol 2018;9:204. [PMID: 29593535 DOI: 10.3389/fphar.2018.00204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
93 Leiser SC, Pehrson AL, Robichaud PJ, Sanchez C. Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. Br J Pharmacol 2014;171:4255-72. [PMID: 24846338 DOI: 10.1111/bph.12782] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
94 Areberg J, Søgaard B, Højer AM. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol Toxicol 2012;111:198-205. [PMID: 22448783 DOI: 10.1111/j.1742-7843.2012.00886.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
95 Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68:60-82. [PMID: 24165478 DOI: 10.1111/ijcp.12350] [Cited by in Crossref: 45] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
96 De Deurwaerdère P, Chagraoui A, Di Giovanni G. Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence. Prog Brain Res 2021;261:161-264. [PMID: 33785130 DOI: 10.1016/bs.pbr.2021.02.001] [Reference Citation Analysis]
97 Grosso C. Future Strategies for the Treatment of Depression. In: Grosso C, editor. Herbal Medicine in Depression. Cham: Springer International Publishing; 2016. pp. 557-71. [DOI: 10.1007/978-3-319-14021-6_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
98 Brivio P, Corsini G, Riva MA, Calabrese F. Chronic vortioxetine treatment improves the responsiveness to an acute stress acting through the ventral hippocampus in a glucocorticoid-dependent way. Pharmacological Research 2019;142:14-21. [DOI: 10.1016/j.phrs.2019.02.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
99 Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16:313-321. [PMID: 22963932 DOI: 10.1017/s1461145712000727] [Cited by in Crossref: 77] [Cited by in F6Publishing: 23] [Article Influence: 8.6] [Reference Citation Analysis]
100 Millan MJ, Rivet J, Gobert A. The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders. J Psychopharmacol 2016;30:1099-128. [DOI: 10.1177/0269881116672342] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
101 Zuena AR, Maftei D, Alemà GS, Dal Moro F, Lattanzi R, Casolini P, Nicoletti F. Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain. Mol Pain 2018;14:1744806918808987. [PMID: 30289053 DOI: 10.1177/1744806918808987] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
102 Jacobsen PL, Harper L, Chrones L, Chan S, Mahableshwarkar AR. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2015;30:255-64. [PMID: 26020712 DOI: 10.1097/YIC.0000000000000081] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
103 Gibb A, Deeks ED. Vortioxetine: First Global Approval. Drugs 2014;74:135-45. [DOI: 10.1007/s40265-013-0161-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
104 Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research. CNS Drugs 2013;27:703-16. [DOI: 10.1007/s40263-013-0071-0] [Cited by in Crossref: 185] [Cited by in F6Publishing: 148] [Article Influence: 23.1] [Reference Citation Analysis]
105 Smagin GN, Song D, Budac DP, Waller JA, Li Y, Pehrson AL, Sánchez C. Histamine may contribute to vortioxetine's procognitive effects; possibly through an orexigenic mechanism. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2016;68:25-30. [DOI: 10.1016/j.pnpbp.2016.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
106 Riga MS, Sanchez C, Celada P, Artigas F. Sub-chronic vortioxetine (but not escitalopram) normalizes brain rhythm alterations and memory deficits induced by serotonin depletion in rats. Neuropharmacology 2020;178:108238. [DOI: 10.1016/j.neuropharm.2020.108238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Citrome L. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 2016;196:225-33. [DOI: 10.1016/j.jad.2016.02.042] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 6.2] [Reference Citation Analysis]
108 Gupta D, Radhakrishnan M, Thangaraj D, Kurhe Y. Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models. Eur J Pharmacol 2014;735:59-67. [PMID: 24747753 DOI: 10.1016/j.ejphar.2014.04.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
109 Kaser M, Zaman R, Sahakian BJ. Cognition as a treatment target in depression. Psychol Med 2017;47:987-9. [DOI: 10.1017/s0033291716003123] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 6.2] [Reference Citation Analysis]
110 Chen G, Nomikos GG, Affinito J, Jacobson W, Zhao Z, Wang S, Xie J. Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine. Clinical Pharmacology in Drug Development 2018;7:880-8. [DOI: 10.1002/cpdd.577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
111 Borhannejad F, Shariati B, Naderi S, Shalbafan M, Mortezaei A, Sahebolzamani E, Saeb A, Hosein Mortazavi S, Kamalzadeh L, Aqamolaei A, Ali Noorbala A, Namazi‐shabestari A, Akhondzadeh S. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double‐blind randomized trial. J Clin Pharm Ther 2020;45:804-11. [DOI: 10.1111/jcpt.13177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Chen G, Lee R, Højer AM, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 2013;33:727-36. [PMID: 23975654 DOI: 10.1007/s40261-013-0117-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 35] [Article Influence: 8.3] [Reference Citation Analysis]
113 Artigas F. Future directions for serotonin and antidepressants. ACS Chem Neurosci 2013;4:5-8. [PMID: 23336036 DOI: 10.1021/cn3001125] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
114 Bronson J, Black A, Dhar M, Ellsworth B, Robert Merritt J. To Market, To Market—2013. Elsevier; 2014. pp. 437-508. [DOI: 10.1016/b978-0-12-800167-7.00027-4] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
115 Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release. CNS Spectr 2015;20:331-6. [PMID: 26062900 DOI: 10.1017/S1092852915000334] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
116 El Mansari M, Lecours M, Blier P. Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacology (Berl) 2015;232:2343-52. [PMID: 25665528 DOI: 10.1007/s00213-015-3870-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
117 Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014;19:121-33. [PMID: 23903233 DOI: 10.1017/S1092852913000540] [Cited by in Crossref: 91] [Cited by in F6Publishing: 30] [Article Influence: 11.4] [Reference Citation Analysis]
118 Erburu M, Muñoz-cobo I, Diaz-perdigon T, Mellini P, Suzuki T, Puerta E, Tordera RM. SIRT2 inhibition modulate glutamate and serotonin systems in the prefrontal cortex and induces antidepressant-like action. Neuropharmacology 2017;117:195-208. [DOI: 10.1016/j.neuropharm.2017.01.033] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
119 Morisot N, Le Moine C, Millan MJ, Contarino A. CRF₂ receptor-deficiency reduces recognition memory deficits and vulnerability to stress induced by cocaine withdrawal. Int J Neuropsychopharmacol 2014;17:1969-79. [PMID: 24800964 DOI: 10.1017/S1461145714000625] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
120 Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry 2013;45:54-63. [PMID: 23602950 DOI: 10.1016/j.pnpbp.2013.04.009] [Cited by in Crossref: 268] [Cited by in F6Publishing: 214] [Article Influence: 33.5] [Reference Citation Analysis]
121 Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 2015;23:1-21. [PMID: 25643025 DOI: 10.1037/a0038550] [Cited by in Crossref: 172] [Cited by in F6Publishing: 117] [Article Influence: 28.7] [Reference Citation Analysis]
122 Jensen JB, du Jardin KG, Song D, Budac D, Smagin G, Sanchez C, Pehrson AL. Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: Evidence for direct 5-HT receptor modulation. European Neuropsychopharmacology 2014;24:148-59. [DOI: 10.1016/j.euroneuro.2013.10.011] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 8.7] [Reference Citation Analysis]
123 Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. J Affect Disord 2018;229:421-8. [PMID: 29331703 DOI: 10.1016/j.jad.2017.12.056] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
124 Bennabi D, Haffen E, Van Waes V. Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research. Front Psychiatry 2019;10:771. [PMID: 31780961 DOI: 10.3389/fpsyt.2019.00771] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
125 Chakroborty S, Geisbush TR, Dale E, Pehrson AL, Sánchez C, West AR. Impact of Vortioxetine on Synaptic Integration in Prefrontal-Subcortical Circuits: Comparisons with Escitalopram. Front Pharmacol 2017;8:764. [PMID: 29123483 DOI: 10.3389/fphar.2017.00764] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
126 He H, Wang W, Lyu J, Zheng J, Guo L, An X, Fan Y, Ma X. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis. Journal of Psychiatric Research 2018;96:247-59. [DOI: 10.1016/j.jpsychires.2017.10.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
127 Guilloux JP, Mendez-David I, Pehrson A, Guiard BP, Repérant C, Orvoën S, Gardier AM, Hen R, Ebert B, Miller S, Sanchez C, David DJ. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology 2013;73:147-59. [PMID: 23721744 DOI: 10.1016/j.neuropharm.2013.05.014] [Cited by in Crossref: 80] [Cited by in F6Publishing: 68] [Article Influence: 10.0] [Reference Citation Analysis]
128 Li Y, Pehrson AL, Budac DP, Sánchez C, Gulinello M. A rodent model of premenstrual dysphoria: progesterone withdrawal induces depression-like behavior that is differentially sensitive to classes of antidepressants. Behav Brain Res 2012;234:238-47. [PMID: 22789402 DOI: 10.1016/j.bbr.2012.06.034] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
129 Bétry C, Pehrson AL, Etiévant A, Ebert B, Sánchez C, Haddjeri N. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT3 receptor antagonism. International Journal of Neuropsychopharmacology 2013;16:1115-27. [DOI: 10.1017/s1461145712001058] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
130 Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder: EFFICACY AND TOLERABILITY OF TWO VORTIOXETINE DOSES IN ACUTE GAD. Hum Psychopharmacol Clin Exp 2014;29:64-72. [DOI: 10.1002/hup.2371] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.1] [Reference Citation Analysis]
131 Cuboni S, Hausch F. Snapshot of antidepressants at work: the structure of neurotransmitter transporter proteins. Angew Chem Int Ed Engl 2014;53:5008-9. [PMID: 24729171 DOI: 10.1002/anie.201310567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
132 Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29:138-149. [PMID: 24257717 DOI: 10.1097/yic.0000000000000018] [Cited by in Crossref: 102] [Cited by in F6Publishing: 28] [Article Influence: 14.6] [Reference Citation Analysis]
133 Artigas F. Serotonin receptors involved in antidepressant effects. Pharmacology & Therapeutics 2013;137:119-31. [DOI: 10.1016/j.pharmthera.2012.09.006] [Cited by in Crossref: 193] [Cited by in F6Publishing: 149] [Article Influence: 24.1] [Reference Citation Analysis]
134 Dale E, Grunnet M, Pehrson AL, Frederiksen K, Larsen PH, Nielsen J, Stensbøl TB, Ebert B, Yin H, Lu D, Liu H, Jensen TN, Yang CR, Sanchez C. The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT3 receptor expressing interneurons: An in vitro study in rat hippocampus slices. Brain Res 2018;1689:1-11. [PMID: 29274875 DOI: 10.1016/j.brainres.2017.12.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
135 Fiorino F, Magli E, Kędzierska E, Ciano A, Corvino A, Severino B, Perissutti E, Frecentese F, Di Vaio P, Saccone I, Izzo AA, Capasso R, Massarelli P, Rossi I, Orzelska-gòrka J, Kotlińska JH, Santagada V, Caliendo G. New 5-HT1A, 5HT2A and 5HT2C receptor ligands containing a picolinic nucleus: Synthesis, in vitro and in vivo pharmacological evaluation. Bioorganic & Medicinal Chemistry 2017;25:5820-37. [DOI: 10.1016/j.bmc.2017.09.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
136 Immadisetty K, Geffert LM, Surratt CK, Madura JD. New design strategies for antidepressant drugs. Expert Opin Drug Discov 2013;8:1399-414. [PMID: 23991860 DOI: 10.1517/17460441.2013.830102] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
137 Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacology & Therapeutics 2015;145:43-57. [DOI: 10.1016/j.pharmthera.2014.07.001] [Cited by in Crossref: 245] [Cited by in F6Publishing: 172] [Article Influence: 40.8] [Reference Citation Analysis]
138 Zohar J, Nutt DJ, Kupfer DJ, Moller H, Yamawaki S, Spedding M, Stahl SM. A proposal for an updated neuropsychopharmacological nomenclature. European Neuropsychopharmacology 2014;24:1005-14. [DOI: 10.1016/j.euroneuro.2013.08.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 36] [Article Influence: 8.7] [Reference Citation Analysis]
139 Dale E, Zhang H, Leiser SC, Xiao Y, Lu D, Yang CR, Plath N, Sanchez C. Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. J Psychopharmacol 2014;28:891-902. [PMID: 25122043 DOI: 10.1177/0269881114543719] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
140 Pehrson AL, Cremers T, Bétry C, van der Hart MG, Jørgensen L, Madsen M, Haddjeri N, Ebert B, Sanchez C. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol 2013;23:133-45. [PMID: 22612991 DOI: 10.1016/j.euroneuro.2012.04.006] [Cited by in Crossref: 101] [Cited by in F6Publishing: 85] [Article Influence: 11.2] [Reference Citation Analysis]
141 Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar AR. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder: Vortioxetine for major depression. Psychiatry Clin Neurosci 2018;72:64-72. [DOI: 10.1111/pcn.12565] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
142 Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr 2015;20:93-7. [PMID: 25831967 DOI: 10.1017/S1092852915000139] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
143 Martis LS, Højgaard K, Holmes MC, Elfving B, Wiborg O. Vortioxetine ameliorates anhedonic-like behaviour and promotes strategic cognitive performance in a rodent touchscreen task. Sci Rep 2021;11:9113. [PMID: 33907240 DOI: 10.1038/s41598-021-88462-7] [Reference Citation Analysis]
144 Liguori C, Ferini-Strambi L, Izzi F, Mari L, Manfredi N, D'Elia A, Mercuri NB, Placidi F. Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis. Br J Clin Pharmacol 2019;85:240-4. [PMID: 30328132 DOI: 10.1111/bcp.13772] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
145 Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat 2014;10:349-54. [PMID: 24570588 DOI: 10.2147/NDT.S39544] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
146 Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment (Engl Ed) 2018;11:48-59. [PMID: 28800937 DOI: 10.1016/j.rpsm.2017.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
147 Carta MG, Pala AN, Finco G, Musu M, Moro MF. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clin Pract Epidemiol Ment Health 2015;11:144-9. [PMID: 25893002 DOI: 10.2174/1745017901511010144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
148 Dale E, Bang-andersen B, Sánchez C. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology 2015;95:81-97. [DOI: 10.1016/j.bcp.2015.03.011] [Cited by in Crossref: 123] [Cited by in F6Publishing: 97] [Article Influence: 20.5] [Reference Citation Analysis]
149 Refsgaard LK, Haubro K, Pickering DS, Stuart SA, Robinson ESJ, Andreasen JT. Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test. Psychopharmacology 2016;233:3763-70. [DOI: 10.1007/s00213-016-4407-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
150 Theunissen EL, Street D, Højer A, Vermeeren A, van Oers A, Ramaekers JG. A Randomized Trial on the Acute and Steady-State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition. Clin Pharmacol Ther 2013;93:493-501. [DOI: 10.1038/clpt.2013.39] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
151 Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2014;10:1297-307. [PMID: 25075188 DOI: 10.2147/NDT.S41387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
152 Witt NA, Lee B, Ghent K, Zhang WQ, Pehrson AL, Sánchez C, Gould GG. Vortioxetine Reduces Marble Burying but Only Transiently Enhances Social Interaction Preference in Adult Male BTBR T + Itpr3 tf /J Mice. ACS Chem Neurosci 2019;10:4319-27. [DOI: 10.1021/acschemneuro.9b00386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]